Analyst: Eli Lilly's planned study comparing obesity effects with Novo Nordisk will grow the market

A new study pitting Lilly’s tirzepatide and Novo’s semaglutide head to head in the obesity indication will intensify competition, says an analyst, noting that there are market benefits to be had.

Photo: Vincent Kessler/Reuters/Ritzau Scanpix

In connection with its second quarter report for 2022, Eli Lilly announced that it would conduct a study comparing the weight-loss efficacy of its own substance tirzepatide, which is marketed as Mounjaro for diabetes, and rival firm Novo Nordisk’s obesity drug Wegovy (semaglutide).

According to Senior Equity Analyst at Sydbank Søren Løntoft Hansen, such a comparison study would lead to increased competition but would also grow the market for obesity treatments on the whole, as the focus on treatments as opposed to just diet and exercise will also intensify.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs